According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:
- Novavax overstated its manufacturing capabilities and downplayed manufacturing issues that would impact its approval timeline for NVX-CoV2373 (the Company’s product candidate as a vaccine for COVID-19);
- as a result, Novavax was unlikely to meet its anticipated Emergency Use Authorization (EUA) regulatory timelines for NVX-CoV2373;
- accordingly, the Company overstated the regulatory and commercial prospects for NVX-CoV2373; and
- as a result, the Company’s public statements were materially false and misleading at all relevant times as a result of the foregoing, defendants’ public statements were materially false and/or misleading at all relevant times.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.
